Arca
Skip to content

Warning Letter to Pure Source LLC

Drugs. See Pure Source LLC's company page or this site's inspections.

On Nov 15, 2019, FDA's CDER sent Pure Source LLC a warning letter.

  • Letter date: Nov 15, 2019
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

Mr. Meyerson:

The Food and Drug Administration has completed the evaluation of corrective actions in response to our Warning Letter (WL # 555240), dated February 20, 2019. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely, /S/ John W. Diehl, M.S. Director, Compliance Branch Office of Pharmaceutical Quality Operations, Division II

CC: Renee Alsobrook, Chief Department of Business and Professional Regulation Division of Drugs, Devices and Cosmetics Compliance and Enforcement 2601 Blair Stone Road Tallahassee, Florida 32399-1047

Record

Recipient
Joel J. Meyerson
FDA site ID (FEI)
3002754162
Cited
—

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.